Long-term effects of spironolactone in peritoneal dialysis patients - sprookjes - yvandenbroek - TriplyDB

Long-term effects of spironolactone in peritoneal dialysis patients

Long-term effects of spironolactone in peritoneal dialysis patients

http://www.wikidata.org/entity/Q30413119

about

Blood Pressure Management in Hemodialysis Patients: What We Know And What Questions Remain.Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End-Stage Renal Disease: New Data But the Controversy Continues.ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II - Management of Various Cardiovascular Complications.Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A.The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial Spironolactone Effect in Hepatic Ischemia/Reperfusion Injury in Wistar Rats Management of hyperkalaemia in chronic kidney disease.Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists.Preserving the peritoneal membrane in long-term peritoneal dialysis patients.Pharmacotherapy of Hypertension in Chronic Dialysis Patients.Mineralocorticoid Receptor Blockade in End-Stage Renal Disease.Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis.Potassium supplementation and long-term outcomes in chronic peritoneal dialysis patients with end-stage renal disease: a propensity score matching study.Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.Spironolactone is effective in treating hypokalemia among peritoneal dialysis patients.

P2860

Q30235413-25BB363D-1724-446F-AD7F-F752AB9CEDAC Q31004378-10152CB4-AE3E-4AC9-8ACC-60E943ECD263 Q35904403-E864BBB9-C08D-4AD1-8199-8B532BE7AA73 Q35992464-C8EF104B-0911-4B26-8DC4-50AFCF9C1678 Q36025666-D2215B3E-93CA-4986-B7F2-F1DC20A3F86F Q36427277-B0C13DA4-EDB4-48B1-9779-411F400D6854 Q38249892-F76CA02F-B260-41D7-AEAA-B6D5B5B557EE Q38560705-A35ACF52-6324-495F-8B13-DD00E2E3CA0F Q38568149-E02514F8-73B6-4DC3-AC15-296EF5F31056 Q38802032-CE8720C2-E37E-4778-8552-91439897EB7B Q38815486-8DA34B21-8F60-41B8-8F33-F11CE990279D Q38837657-1D9D7958-C7D1-4205-9882-4A786F938A57 Q40521456-B4844F74-5D12-4E48-BA83-2DDEAD7FEEDD Q41877664-1849128C-FCFC-4E7D-B9AA-937E00395BA2 Q47134104-EC82ED30-BBAD-4327-A734-3B76FCB72FE2

P2860

Long-term effects of spironolactone in peritoneal dialysis patients

http://www.wikidata.org/entity/Q30413119

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Long-term effects of spironolactone in peritoneal dialysis patients

@ast

Long-term effects of spironolactone in peritoneal dialysis patients

@en

type

label

Long-term effects of spironolactone in peritoneal dialysis patients

@ast

Long-term effects of spironolactone in peritoneal dialysis patients

@en

prefLabel

Long-term effects of spironolactone in peritoneal dialysis patients

@ast

Long-term effects of spironolactone in peritoneal dialysis patients

@en

P1433

Q30413119-9A4B6B0A-FBF3-4FD0-AE8F-4BD0FF855D43

P1476

Q30413119-F10C8D1C-FE1F-4ED5-8329-0C5870485BE9

P2093

Q30413119-1D4D646B-B8F2-4EAB-B60A-05A536E807DD

Q30413119-1E8D2B33-D27A-4A18-91EB-6B4692E1F9DE

Q30413119-254981B0-4B59-4958-AEB8-D9B1B78C9CD4

Q30413119-7F3F974E-A9CF-413C-8835-CDCEB3DC727E

Q30413119-AB82284C-6FC3-4548-AA85-28161E42E2A9

Q30413119-AC536A20-129E-4215-8D16-501B71BA4045

Q30413119-B5C870B4-2C58-4D28-AE08-7449F39C1116

Q30413119-B8C210EF-AB80-457E-961E-892CC08BC2EE

Q30413119-C290E2F6-01A5-48FB-92A4-99A4F7AF71C0

Q30413119-CF9B1FD2-1CC7-493B-A09E-443E56717BBB

P2860

Q30413119-01D9BBFE-7198-4A1D-9BF8-801B22636B1B

Q30413119-02F624A1-BE66-4D83-8D84-B70A70C67720

Q30413119-051E8EE4-88DC-41D5-BD66-B6DB5817A558

Q30413119-06D21DB3-8B5E-4824-9492-2B06AD3DDFCD

Q30413119-0BE81269-D73E-45F9-B99B-E2A8E99BE3BF

Q30413119-118306DA-7F3B-4C87-A710-4B2FD4D38DBB

Q30413119-13261636-1EA5-4C46-A633-6090D13AF4DC

Q30413119-1CF3FF48-BEEF-49B7-B37B-08DC7483B437

Q30413119-1F723EE6-F263-4894-9F00-5CD8BFF8E6FD

Q30413119-2534F520-3070-4AC5-A854-08C0C286731C

P304

Q30413119-D2CA63DB-EAC7-4C5D-8F1D-6631C1CDAD3E

P31

Q30413119-F617858A-F75A-4F74-9D97-990404B4EAA7

P356

Q30413119-DCD7A964-4543-47B9-A26A-AE92DF60DBEF

P433

Q30413119-658EFDE3-5C5A-43D2-A3B3-2F391DD72B83

P478

Q30413119-EF1600EF-4250-44B8-8425-9177A06A7912

P50

Q30413119-3A01D85D-2350-4537-A385-7C8D568C58D0

P577

Q30413119-92199480-B6E7-4917-8D5B-EF67544DE5A0

P698

Q30413119-9A5E67BC-2CCF-4434-8069-480590B7A812

P921

Q30413119-F9C392C6-6588-4B72-B87B-E8D978DE6695

P932

Q30413119-3A3A438C-128F-48E2-846B-02FA5EDFBF9B

P356

P1433

Journal of the American Society of Nephrology

P1476

Long-term effects of spironolactone in peritoneal dialysis patients

@en

P2093

Hirofumi Tamai

http://www.w3.org/2001/XMLSchema#string

Hiroshige Ohashi

http://www.w3.org/2001/XMLSchema#string

Isao Ito

http://www.w3.org/2001/XMLSchema#string

Masanobu Horie

http://www.w3.org/2001/XMLSchema#string

Masashi Mizuno

http://www.w3.org/2001/XMLSchema#string

Nagoya Spiro Study Group

http://www.w3.org/2001/XMLSchema#string

Seiichi Matsuo

http://www.w3.org/2001/XMLSchema#string

Shoichi Maruyama

http://www.w3.org/2001/XMLSchema#string

Takeyuki Hiramatsu

http://www.w3.org/2001/XMLSchema#string

Tatsuaki Matsubara

http://www.w3.org/2001/XMLSchema#string

P2860

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Less subclinical atherosclerosis in Japanese men in Japan than in White men in the United States in the post-World War II birth cohort.

Chronic kidney disease: effects on the cardiovascular system.

Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin

The importance of residual kidney function for patients on dialysis: a critical review.

Left ventricular mass in chronic kidney disease and ESRD.

Cardiovascular risk in the peritoneal dialysis patient.

P304

1094-1102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2013030273

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Hirotake Kasuga

P577

2013-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24335969

http://www.w3.org/2001/XMLSchema#string

P921

P932

4005296

http://www.w3.org/2001/XMLSchema#string